PRNewsWire
18 Oct 2025, 14:00 UTC · 48w ago
Verdict
Headline takes no side. We score LRMR −0.90 across three claims — strongly bearish.
−0.90strongly bearish
More negative than 90% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Seven participants in a long-term study of Nomlabofusp for Friedreich's Ataxia reported anaphylaxis or severe allergic reactions.
More negative than 99% of claims this week
Pomerantz LLP is investigating Larimar Therapeutics for potential securities fraud or unlawful business practices.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 87% of claims this week
Larimar Therapeutics' stock price dropped 33.66% to $3.38 following the release of the study data on September 29, 2025.
More negative than 71% of claims this week
Which stocks this story touches
More negative than 90% of ticker scores this week
The company is under investigation for securities fraud following a 33.66% stock price drop due to severe allergic reactions in a clinical study.
More negative than 81% of ticker scores this week
A class action lawsuit has been filed against the company.
More negative than 81% of ticker scores this week
The company is the subject of an investigation by Pomerantz LLP on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
4h ago
−8.0%
Price agrees with the score
$3.87 vs $4.20 close before publication (Oct 17) · not market-adjusted
LRMR chart →
